NVIDIA
NVDA
Adobe
ADBE
Tesla
TSLA
4
Netflix
NFLX
5
Qualcomm
QCOM
US Stock MarketDetailed Quotes
RGNX Regenxbio
- 6.720
- +0.170+2.60%
Close Mar 14 16:00 ET
- 6.730
- +0.010+0.15%
Post 18:01 ET
336.58MMarket Cap-1.46P/E (TTM)
7.820High6.620Low1.60MVolume7.070Open6.550Pre Close11.26MTurnover3.89%Turnover RatioLossP/E (Static)50.09MShares23.14052wk High1.30P/B276.64MFloat Cap5.62052wk Low--Dividend TTM41.17MShs Float85.100Historical High--Div YieldTTM18.32%Amplitude5.620Historical Low7.037Avg Price1Lot Size
About Regenxbio Company
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
Company Profile
SymbolRGNX
Company NameRegenxbio
Listing DateSep 17, 2015
Issue Price22.00
Founded2008
CEOMr. Curran Simpson
MarketNASDAQ
Employees344
Fiscal Year Ends12-31
Address9804 Medical Center Drive
CityRockville
ProvinceMaryland
CountryUnited States of America
Zip Code20850
Phone1-240-552-8181
Websitehttp://www.regenxbio.com
Company Executives
- Name
- Position
- Salary
- Curran Simpson
- Director, President and Chief Executive Officer
- 2.95M
- Dr. Olivier Danos, PhD
- Executive Vice President and Chief Scientific Officer
- 2.99M
- Patrick J. Christmas
- Executive Vice President and Chief Legal Officer
- --
- Stephen Pakola, M.D.
- Executive Vice President and Chief Medical Officer
- 3.31M
- Mitchell Chan
- Executive Vice President, Chief Financial Officer and Principal Accounting Officer
- --
- Kenneth T. Mills
- Chairman of the Board
- 5.92M
- Allan M. Fox
- Director
- 354.98K
- Dr. Jean Bennett, M.D.,Pd.D
- Independent Director
- 324.98K
- Dr. Alexandra Glucksmann, PhD
- Independent Director
- 327.48K
- Daniel Tasse
- Lead Independent Director
- 334.98K
- Dr. David C. Stump,M.D.
- Independent Director
- 339.98K
- Jennifer Zachary
- Independent Director
- 329.98K
- Dr. Argeris N. Karabelas, PhD
- Independent Director
- 352.48K
- George V. Migausky
- Independent Director
- 339.98K
Trending Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
FOMC leaves rates unchanged, how will you adjust your portfolio?
FOMC left the target Federal Funds rate unchanged at at target of 4.25%-4.5%, how will you adjust your portfolio?
Moo Live
Jan 30 03:25
FOMC Press Conference, January 29, 2025